Search
Close this search box.

CAN.HEAL project

A new approach

Cancer is now being targeted through a novel integration of genomics in clinical care and public health, known as CAN.HEAL. As the name suggests, this is bringing unprecedented power to bear in tackling and solving the challenges that cancer poses to patients, their relatives, and the population at large.

A Europe-wide consortium is set-up? to exploit unexplored synergies in public health and cancer genomics. This deployment of innovation has won backing from the European Commission for its role in meeting the ambitions of the Europe Beating Cancer plan and the Mission on Cancer, and. helping national cancer plans across Europe.

The project aims at aligning clinical and population-based interventions. By exploiting the increasing wealth of data on genomes it will allow better and earlier diagnosis. And by taking account of regulatory, scientific, economic, research and gender perspectives, it will increasingly make it possible to give the right treatment to the right patient at the right time. This is not only better for patients: it can also bring benefits to health care systems. Improved diagnoses and more effectively targeted treatments can help to reduce lost time for patients and doctors, and avoid waste of resources. The two strands of the project – care and protection – are reflected in the title CAN.HEAL.

A quarterly newsletter (sign up here) will provide regular information on progress and highlight the work of the partners as they drive the initiative forward. This inaugural issue provides an overview of the project and an outline of the objectives and work packages. As the project evolves, further information will appear on the project’s twitter account (@CAN.HEAL) and project website (URL), and can be obtained directly from the project coordinator (xx@sciensano.be).

''CAN.HEAL has the goal of acting as a flagship for cooperation among member states and regional authorities, bridging the gap between public health genomics and diagnostics.''
Marc Van den Bulcke
Sciensano
The overall project coordinator

How does it Can.Heal work?

Profiling of genomic modifications with new technology has become a major asset in tackling cancer, and CAN.HEAL springs from the recognition that both patients and citizens can benefit from a concerted approach that embraces both the clinical and public health aspects of personalised care.

 

The clinical arm of this dual approach focuses on applying next-generation sequencing technology to detect different types of alterations with a potential clinical utility. And in the public health arm, bringing new precision can help provide the right intervention to the right population at the right time, with the goal of improving health for all. 

 

The beneficiaries range from cancer healthcare professionals and researchers to cancer patients, citizens and cancer healthcare policy makers. Patients and citizens will receive more effective clinical support, healthcare professionals will gain a broader view on the cancer of their patient or the risk of the citizen, and healthcare policy makers will be offered recommendations for integrated systems to lower the cancer burden of the population and increase quality of life. As the initiative develops, the target population will expand to include the health community at large as well as policy makers beyond the healthcare sphere.

The potential of Can.Heal project

The potential is enormous. It is now well-established that 40% of cancers are preventable. But in addition, there is increasing clarity over the hitherto unappreciated and underestimated burden of genetic susceptibility that gives rise to cancer risks. Making better use of large population-based studies and biorepositories, coupled with appropriate cancer genomics studies on health and sick people, can deliver invaluable new information on prevention.

 

The clinical aspect of CAN.HEAL will allow EU cancer centres to

·         take advantage of national initiatives to structure omics use in patient care, with harmonized data interpretation and facilitated treatment decisions

·         improve equity  by sharing data on similar diagnostic and therapeutic approaches for patients with comparable cancer profiles across the EU

·         exploit molecular tumour profiling biomarkers of cancer predisposition to allow better counselling of family members regarding cancer risk.

The public health aspect of CAN.HEAL will generate

·         novel insights in estimating cancer risks in healthy populations, by using polygenic risk score analysis within population-wide interventions

·         identification of people at risk in health systems through testing relatives of affected individuals

 

·         strategies for remote genetic counselling and telegenetics, based on incidental findings on cancer status from genetic screening interventions 

Fitting into the EU strategy

The initiative brings together two specific strands of current EU health planning: ‘Cancer Diagnostic and Treatment for All’, and ‘Genomics for Public Health’, and aims at creating a continuum of prevention, diagnosis, prognosis and treatment.  

 

CAN.HEAL has synergies with a wide range of projects launched within the Europe Beating Cancer Plan, the Mission for Cancer and the Digital Europe strategy. It is complementary to numerous European programmes in genomics in cancer, and to multiple national and international initiatives integrating genomics into healthcare systems at clinical or public health level. It will link to recent EU initiatives in the fourth health programme (EU4H), to the JRC Knowledge Centre on Cancer, ICPerMed, the 1+Million genomes initiative and others. Its outcomes will contribute to the goals of the updated EU pharmaceutical legislation, the European Health Data Space, the implementation of the In Vitro Devices Regulation as well as other future projects.

 

 

Ongoing EU activities are engaged as use cases for the initiative, so as to provide evidence or tools for developing a platform that can pave the way for implementation at a broader scale.

“The expected impact of CAN.HEAL will be stronger links between European member states and regions setting up personalised healthcare."
Iwona Lugowska
Maria Skłodowska Curie Memorial Cancer Centre
Warsaw

Why is CAN.HEAL necessary

Coordinating policies and innovation programmes in personalised medicine is an urgent need.  CAN.HEAL  is the response to the evident lack of international multi-centric collaboration necessary to advance large-scale high quality, viable prevention, diagnosis and treatment of cancer.

 

EU and member state policy makers require the best possible information and advice in minimising barriers to the uptake of personalised medicine at the political level, and the continuous technical dialogue offered by CAN.HEAL is capable of feeding into that. Patients can benefit in unprecedented ways – and so too can healthcare systems.

 

The process  can improve value for money in cash-strapped healthcare systems that are struggling with ageing populations, increased co-morbidities and chronic diseases, and health workforce shortages at the same time as dealing with a new clinical trial paradigm in the wake of the discovery of ever more rare diseases, A restructuring care delivery has to be envisaged, with new care models, strategies and investments in a combination of novel bottom-up and top-down approaches.

The challenges of Can.Heal project

Four clear challenges present themselves.

  • The results obtained by complex genomic profiling require harmonization and standardization to obtain impact from these international multi-centric collaboration efforts.
  • The sharing and analysis of outcomes require a secure environment.
  • Limited public and professional understanding of genomics is a continuing handicap to effective implementation of innovative approaches – a handicap that is also influential at the level of many policymakers.
  • And the rights of all individuals to be fully informed on where and how their genomics data are being applied must be guaranteed at all times.
Rapidly emerging new approaches in genomics, together with the explosion in potentially paradigm-changing Big Data streams, should allow Europe to put its millions of potential patients across different regions at the heart of a revolution in care, boosting quality and overcoming divergences in access. But for that, innovation has to be brought into healthcare systems at an effective pace.

“CAN.HEAL will support the necessary coordination in a much smarter fashion to help address take-up, and this is at the heart of what CAN.HEAL is all about,”
Marc Van Den Bulcke
CAN.HEAL Project Coordinator

Objectives and outcomes

Key objectives to the initiative are:

  • developing a lifespan approach to prevention, diagnosis and treatment
  • developing tools and procedures to integrate and align clinical and population-based interventions dependent on genomics data sourced through massive parallel genome analysis
  • national capacity building and specific education and training for health workers in genomics and cancer care and control
  • a boost to genomic profiling in paediatric cancers
  • deeper ethical and legal consents towards access to medical information

 

Specific focuses of the work will include implementing NGS-based and liquid biopsy assays in clinical practice, establishing a quality management system for NGS-based clinical assays, standardizing assay-reporting outcomes, developing ethical and legal data governance for re-use of genomic data , and developing recommendations, guidelines, and best practices.

 

The work will be conducted in 14 work packages, covering Coordination, Communication, dissemination and outreach, Evaluation, Genome of Europe, Prevention/early detection,  Polygenic risk scores and decision support tools, Diagnosis and treatment decision via Molecular Tumour Boards, Building clinical utility, Treatment and follow-up, Oncology decision support tools, NGS including liquid biopsy, Law, ethics and citizen engagement, Education & training, and Health care system implementation.

 

Upcoming events

The CAN.HEAL agenda is under finalisation and will be published in early 2023.

Plenary meetings of CAN.HEAL are tentatively scheduled for Rome in late spring 2023 (27-28 April), Berlin in autumn 2023 and Paris in early spring 2024.

February 7 ‘Propelling early diagnosis into the twenties for cancer patients’. The importance of CAN.HEAL will be flagged up with MEPs and the European Commission at a meeting in the European Parliament on February 7 (shortly after World Cancer Day) hosted by  EAPM, a co-lead of CAN.HEAL for communications.

“Healthcare actors as well as patients involved in this initiative will be able to see how the EU is tackling the challenges of cancer, and will have access to state-of-the-art analyses and the opportunity to share their views to ensure the concept of access and diagnostics for all becomes a reality.”
Gennaro Giliberto
Italy's Instituto Nazionale Tumori Regina Elena
Rome

For more information, please contact:

Denis Horgan  (WP Lead Communication and Policy)

Els Van Valckenborgh: (project manager)

Partners

aarhus
acil
biopsy
certh
charite
institut curie
digicore
eapm
ecpc
ellok
erasmus
fisabio
gent
hannover
hcl
ibsal
ic
ico
iecyc
ihop
ijb
insa
inserm
iss
jessa
kul
lbmc
liege
mft
muw
nci
oil
oiv
rivm
salut
sciensano
tartu
tubingen
uccsh
ucsc
uhkt
uke
unilu
National_Research_Institute_of_Oncology_logo